Does anything work as well as Tysabri?
Tysabri is considered one of the three highly active disease modifying therapies for relapsing forms of MS. The other two highly active disease modifying therapies are Ocrelizumab (Ocrevus) and alemtuzumab (lemtrada). Ocrevus is also approved for progressive forms of MS
Some people also consider Daclizumab (Zinbryta) one of the highly active MS therapies, but I consider it a class II agent
Revere (Rip) Kinkel MD
Professor of Clinical Neurosciences
Director of the Multiple Sclerosis Program
Clinical Neurosciences Director
University of California San Diego